Mark Schoenberg - 09 Sep 2024 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role: Chief Medical Officer
Signature: /s/ Jason D. Smith, Attorney-in-Fact
Issuer symbol: URGN
Transactions as of: 09 Sep 2024
Net transactions value: -$11,236
Form type: 4
Filing time: 12 Sep 2024, 13:54:09 UTC
Previous filing: 11 Jun 2024
Next filing: 04 Feb 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	URGN	Ordinary Shares	Options Exercise		+1,666	+1.2%		145,950	09 Sep 2024	Direct	F1
transaction	URGN	Ordinary Shares	Sale	$11,236	-859	-0.59%	$13.08	145,091	09 Sep 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	URGN	Restricted Stock Units	Options Exercise	$0	-1,666	-33%	$0.000000	3,334	09 Sep 2024	Ordinary Shares	1,666		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2	Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
F3	The reporting person was granted RSUs on September 7, 2023 representing 5,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024.